SCHEDULE: BlackRock Discloses 5.6% Stake in Protara Therapeutics
Beneficial Ownership Disclosure
BlackRock, Inc. has filed a Schedule 13G, revealing a 5.6% beneficial ownership stake in Protara Therapeutics, Inc. as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,143,880 shares of Protara Therapeutics, Inc. common stock.
- This ownership represents 5.6% of the total outstanding common shares of Protara Therapeutics, Inc.
- BlackRock holds sole voting power over 2,094,178 shares and sole dispositive power over 2,143,880 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- The beneficial ownership is attributed to various business units of BlackRock, Inc. and its subsidiaries and affiliates, including BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- A significant institutional investment by BlackRock, Inc. can be viewed as a vote of confidence in Protara Therapeutics, Inc.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in Protara Therapeutics, Inc., a company in the biotechnology or pharmaceutical sector, by one of the world's largest asset managers. Such disclosures are routine for large investors crossing ownership thresholds and do not inherently provide specific insights into broader industry trends beyond general investment activity.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a major institutional investor like BlackRock could be perceived positively, potentially increasing investor confidence and liquidity.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the new Power of Attorney by BlackRock, Inc. |
| 06/30/2025 | Date of event which requires the filing of this statement, representing the beneficial ownership reporting period end. |
| 07/17/2025 | Date of filing of the Schedule 13G statement by BlackRock, Inc. |
Keywords
BlackRock, Protara Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.